AXL-targeted agents inhibited the growth of FLT3mut AML cell lines and FLT3-ITDmut AML primary samples in a dose-dependent manner, and synergistically inhibited proliferation and induced apoptosis of MV4-11/AC220 and FLT3i-resistant AML blast cells when combined with Quizartinib. The gene discussed is FLT3; the disease is acute myeloid leukemia.